Reaction

Toe Amputation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,040 reports · 57 co-occurring drugs

As of the last recalculation, Toe Amputation appears in 5,040 FAERS reports alongside 57 co-occurring drug terms. The strongest observed disproportionality signal is CANAGLIFLOZIN (PRR 535.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Canagliflozin	2,195	535.9	578.5
Empagliflozin	175	11.1	11.1
Insulin Human	98	10.4	10.4
Human Insulin	28	9.3	9.3
Insulin Aspart	131	8.4	8.4
Insulin Glulisine	20	8.2	8.2
Insulin Glargine-Yfgn	37	7.0	7.0
Patiromer	23	6.9	6.9
Insulin Glargine	371	6.6	6.6
Insulin	81	6.1	6.1
Insulin Degludec	32	5.7	5.7
Sitagliptin And Metformin Hydrochloride	29	5.6	5.6
Dapagliflozin	41	5.4	5.4
Sevelamer Carbonate	15	5.4	5.4
Linagliptin	20	4.5	4.5
Metolazone	12	4.4	4.4
Insulin Lispro	139	4.2	4.2
Glipizide	62	4.2	4.2
Glyburide	24	4.1	4.1
Sitagliptin	68	3.9	3.9
Metformin Er 500 Mg	263	3.8	3.8
Metformin Er 750 Mg	263	3.8	3.8
Bosentan	44	3.6	3.6
Agalsidase Beta	8	3.6	3.6
Metformin	296	3.6	3.6
Glimepiride	33	3.5	3.5
Paricalcitol	11	3.2	3.2
Liraglutide	35	2.9	2.9
Ranolazine	7	2.8	2.8
Darbepoetin Alfa	36	2.8	2.8
Heparin Sodium	9	2.7	2.7
Clopidogrel	124	2.6	2.6
Eplerenone	8	2.6	2.6
Tocilizumab	69	2.5	2.5
Risankizumab-Rzaa	48	2.4	2.4
Pioglitazone	24	2.3	2.3
Cinacalcet Hydrochloride	25	2.2	2.2
Macitentan	37	2.2	2.2
Desoximetasone	10	2.2	2.2
Metformin Hcl	28	2.1	2.1
Vibegron	4	2.1	2.1
Bosutinib	4	1.8	1.8
Oral Semaglutide	29	1.6	1.6
Tofacitinib	68	1.5	1.5
Methoxy Polyethylene Glycol-Epoetin Beta	4	1.5	1.5
Ranibizumab	9	1.4	1.4
Ambrisentan	38	1.3	1.3
Ixekizumab	11	1.2	1.2
Dornase Alfa	5	1.1	1.1
Relugolix	6	1.1	1.1
Exenatide	13	1.0	1.0
Bimekizumab	5	1.0	1.0
Abiraterone Acetate	9	0.9	0.9
Dulaglutide	18	0.8	0.8
Droxidopa	4	0.8	0.8
Pimavanserin Tartrate	8	0.6	0.6
Evolocumab	18	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.